The current P/E ratio for Catalyst Pharmaceuticals stock as of May 2, 2024 is 22.42. This is calculated based on the current EPS of $0.67 and the stock price of $15.02 per share. The PE ratio has increased by 20% from the past four quarters average of 18.6.
The average historical PE ratio of Catalyst Pharmaceuticals for the last five years is 16.45. The current price-to-earnings ratio of 22.42 is 36% more than the historical average. In the past five years, CPRX's PE ratio reached its highest point in the Sep 2019 quarter at 59, when the stock price was $5.31 and the EPS was $0.09. The lowest point was recorded in the Sep 2020 quarter, when it reached 4.3 with a price of $2.97 and an EPS of $0.69.
Maximum annual increase: 284.05% in 2021
Maximum annual decrease: -61.65% in 2020
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 25.09 | 7.91% |
| 2022 | 23.25 | 30.47% |
| 2021 | 17.82 | 284.05% |
| 2020 | 4.64 | -61.65% |
| 2019 | 12.1 | N/A |
| 2018 | N/A | N/A |
| 2017 | N/A | N/A |
| 2016 | N/A | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
The current PE ratio of CPRX is above its 3, 5 and 10-year historical averages.
When compared to its peers ABT and PFE, CPRX's PE ratio is lower, but it is higher than JNJ's. Catalyst Pharmaceuticals is presently trading at a lower PE ratio (22.42) than its peer group average of 47.97.
| Stock name | PE ratio | Market cap |
|---|---|---|
| JNJ Johnson & Johnson | 9.78 | $359.25B |
| CPRX Catalyst Pharmaceuticals Inc | 21.97 | $1.73B |
| ABT Abbott Laboratories | 32.79 | $184.23B |
| PFE Pfizer Inc | 73.18 | $157.04B |
| BMRN Biomarin Pharmaceutical Inc | 75.72 | $15.67B |
| SRPT Sarepta Therapeutics Inc | 326.22 | $12.64B |
CPRX stock has a price to earnings ratio of 22.42 as of May 2, 2024.
As an average over the last 3 years, CPRX stock has a PE ratio of 17.15.
As an average over the last 5 years, CPRX stock has a PE ratio of 16.45.
Over the last five years, the quarterly PE ratio reached a historic high of 59 in the Sep 2019 quarter.
The current price to earnings ratio of CPRX is 36% higher than the 5-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the earnings per share(EPS) for the last 12 months. As of today (May 2, 2024), Catalyst Pharmaceuticals's stock price is $15.02. The earnings per share for the trailing twelve months (TTM) ending Dec 2023 is $0.67. Therefore, Catalyst Pharmaceuticals's price to earnings ratio for today is 22.42. PE RATIO(22.42) = STOCK PRICE($15.02) / TTM EPS($0.67)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.